BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16267076)

  • 1. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?
    Galasko GI; Barnes SC; Collinson P; Lahiri A; Senior R
    Eur Heart J; 2006 Jan; 27(2):193-200. PubMed ID: 16267076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides.
    Ng LL; Loke IW; Davies JE; Geeranavar S; Khunti K; Stone MA; Chin DT; Squire IB
    J Am Coll Cardiol; 2005 Apr; 45(7):1043-50. PubMed ID: 15808762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.
    de Lemos JA; McGuire DK; Khera A; Das SR; Murphy SA; Omland T; Drazner MH
    Am Heart J; 2009 Apr; 157(4):746-53.e2. PubMed ID: 19332205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide].
    Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G
    G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of the B type natriuretic peptide, electrocardiography, and portable echocardiography for the assessment of patients from the community with suspected heart failure.
    Lim TK; Dwivedi G; Hayat S; Collinson PO; Senior R
    Echocardiography; 2007 Mar; 24(3):228-36. PubMed ID: 17313633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width.
    Goode KM; Clark AL; Cleland JG
    Int J Cardiol; 2008 Nov; 130(3):426-37. PubMed ID: 18178273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.
    Ng LL; Pathik B; Loke IW; Squire IB; Davies JE
    Am Heart J; 2006 Jul; 152(1):94-101. PubMed ID: 16824837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of primary care electrocardiography for the prediction of left ventricular systolic dysfunction in patients with suspected heart failure.
    Lim TK; Collinson PO; Celik E; Gaze D; Senior R
    Int J Cardiol; 2007 Jan; 115(1):73-4. PubMed ID: 16777249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction.
    Goetze JP; Mogelvang R; Maage L; Scharling H; Schnohr P; Sogaard P; Rehfeld JF; Jensen JS
    Eur Heart J; 2006 Dec; 27(24):3004-10. PubMed ID: 17118955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for left ventricular systolic dysfunction in high-risk patients in primary-care: a cost-benefit analysis.
    Goode KM; Clark AL; Bristow JA; Sykes KB; Cleland JG
    Eur J Heart Fail; 2007 Dec; 9(12):1186-95. PubMed ID: 18006378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?
    Galasko GI; Lahiri A; Barnes SC; Collinson P; Senior R
    Eur Heart J; 2005 Nov; 26(21):2269-76. PubMed ID: 16040618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of different strategies for identifying asymptomatic left ventricular dysfunction and pre-clinical (stage B) heart failure in the elderly. Results from 'PREDICTOR', a population based-study in central Italy.
    Mureddu GF; Tarantini L; Agabiti N; Faggiano P; Masson S; Latini R; Cesaroni G; Miceli M; Forastiere F; Scardovi AB; Uguccioni M; Boccanelli A
    Eur J Heart Fail; 2013 Oct; 15(10):1102-12. PubMed ID: 23787717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the most useful and cost-effective strategy to screen for left ventricular systolic dysfunction in clinical practice?
    Yamada A; Yamada Y; Okada K
    Eur Heart J; 2006 Jun; 27(11):1382-3; author reply 1383. PubMed ID: 16613931
    [No Abstract]   [Full Text] [Related]  

  • 14. Screening for left ventricular systolic dysfunction: the use of B-type natriuretic peptide.
    Freitag MH; Vasan RS
    Heart Fail Monit; 2003; 4(2):38-44. PubMed ID: 14724717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population.
    Nielsen OW; McDonagh TA; Robb SD; Dargie HJ
    J Am Coll Cardiol; 2003 Jan; 41(1):113-20. PubMed ID: 12570953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effective strategies to screen for left ventricular systolic dysfunction in the community--a concept.
    Senior R; Galasko G
    Congest Heart Fail; 2005; 11(4):194-8, 211. PubMed ID: 16106121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular systolic dysfunction in rheumatoid disease: an unrecognized burden?
    Bhatia GS; Sosin MD; Patel JV; Grindulis KA; Khattak FH; Hughes EA; Lip GY; Davis RC
    J Am Coll Cardiol; 2006 Mar; 47(6):1169-74. PubMed ID: 16545648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients.
    Romano S; Necozione S; Guarracini L; Fratini S; Cisternino P; di Orio F; Penco M
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):238-44. PubMed ID: 19262210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography.
    Ng LL; Loke I; Davies JE; Khunti K; Stone M; Abrams KR; Chin DT; Squire IB
    Eur J Heart Fail; 2003 Dec; 5(6):775-82. PubMed ID: 14675856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BNP in the community - still work to be done..
    Rao A; Hodgson L; Pearce D; Walsh J
    Int J Cardiol; 2008 Feb; 124(2):228-30. PubMed ID: 17363081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.